Transformation of Cancer Research Pipeline at Hoffmann-La Roche from 1950s to 2000s

Strategic Insights -

The University of Manchester recently released a study on the history of the research and development pipeline for anticancer drugs at pharmaceutical company Hoffmann-La Roche. The research analyzed the transformation from a chemistry-driven innovation model to one organized around molecular biology and collaborations with biotech companies. The study highlighted the shift in targeting cancer using relatively expensive biological compounds, exemplified by the case studies of Roche's oncology drugs 5-Fluoro-Uracil, procarbazine, rituxan, trastuzumab, and bevacizumab.

Key Takeaways:

  • The history of Roche's oncology drugs illustrates a major transformation in the pharmaceutical industry, from a chemistry-driven innovation model to one organized around molecular biology and collaborations with biotech companies.
  • The transformation was driven by the development of oncogenes and monoclonal antibody technology, which has been less extensively studied.
  • The case studies examined by the research include 5-Fluoro-Uracil, procarbazine, rituxan, trastuzumab, and bevacizumab, all of which were approved by the FDA between 1962 and 2004.
  • The development of monoclonal antibody compounds marked a shift towards a new interpretation of an old paradigm, where these antibodies can be employed to treat conditions caused by microbes in addition to cancer.
  • The research suggests that the transformation of the cancer research pipeline at Hoffmann-La Roche was influenced by the programmatic publications of Jurgen Drews, Roche's Head of Research in the late 1980s and 1990s.

Statistics:

  • The FDA approved 5-Fluoro-Uracil in 1962.
  • Procarbazine received FDA approval in 1969.
  • Rituximab (Rituxan or Mabthera) was approved by the FDA in 1997.
  • Trastuzumab (Herceptin) received FDA approval in 1998.
  • Bevacizumab (Avastin) was approved by the FDA in 2004.
  • Between 1962 and 2004, the FDA approved a total of five anticancer drugs developed by Hoffmann-La Roche.

Sources:

  • From chemotherapy to biotechnology: the transformation of the cancer research pipeline at Hoffmann-La Roche. Humanities & Social Sciences Communications, 2025,12(1):1-10.
  • https://doi-org.sdpl.idm.oclc.org/10.1057/s41599-025-04812-0 (a free version of the journal article)